---
schema_version: "secwatch.filing_event.v1"
accession: "0001792044-25-000042"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:55:05.407852+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch

## Summary
- Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.
- Submitted NDA for low-dose estrogen weekly patch; advancing pipeline.
- Acquired Aculys Pharma, gaining rights to Pitolisant (Japan) and Spydia (Japan & Asia-Pacific).
- Year-to-date capital return >$920M, including $500M in share repurchases.
- CEO cites strong execution and strategic review for sustainable growth in 2026.

## SEC filing metadata
- accession: 0001792044-25-000042
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/0001792044-25-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/vtrs-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001792044-25-000042
- JSON: https://secwatch.observer/filing/0001792044-25-000042.json
- Plain text: https://secwatch.observer/filing/0001792044-25-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.